SKN | Barclays Maintains Overweight Rating on Axon Despite Cutting Price Target to $507

Key Takeaways:

• Barclays lowered its Axon Enterprise price target to $507 from $688 following the company’s third-quarter results, while retaining its Overweight rating.
• The revised target implies approximately 62% upside from Axon’s November 6 closing price of $313, although the adjustment reflects a more cautious assessment of near-term execution and cash flow.
• Barclays’ position comes amid strong software growth and contracted bookings, but delayed federal counter-drone deployments and weaker free cash flow guidance have introduced additional uncertainty.

Barclays has recalibrated its outlook on Axon Enterprise (NASDAQ: AXON) following a sharp market reaction to the company’s third-quarter results. The bank reduced its price target from $688 to $507 but maintained its Overweight rating, indicating that it continues to see potential value despite the deterioration in near-term expectations. At Axon’s November 6 closing price of $313, the revised target represents approximately 62% potential appreciation. However, the lower target also signals that Barclays has adjusted its expectations following operational and cash flow setbacks.

Barclays Adjusts Its Valuation Following Weaker Guidance

Axon shares declined approximately 18% to $313 on November 6 after its quarterly report, leaving the stock down around 45% for the year. Revenue increased 28% year over year to $909 million, but remained below analyst expectations of approximately $937 million.

A key issue was the delay of three federal Dedrone counter-drone deployments. Axon removed approximately $130 million in expected revenue associated with these projects from its 2026 outlook. The company also reduced its free cash flow target to $350 million–$400 million from $450 million. These developments provide context for Barclays’ decision to lower its target, although the available report does not disclose the bank’s precise valuation methodology or the individual assumptions behind its revised estimate.

Cash Flow Remains Central to the Investment Assessment

The reported financial figures highlight why cash generation has become an important consideration. Axon’s free cash flow declined to $75.1 million in 2025 from $329.5 million in 2024 and was negative $55.6 million during the first half of 2026. The company also issued $1.15 billion in convertible notes in September.

For Barclays, the distinction between revenue growth and cash flow performance is particularly relevant when assessing the sustainability of Axon’s expansion. The company expects approximately $450 million in fourth-quarter free cash flow, according to the report. Delivery against that expectation could help clarify whether the recent weakness reflects temporary timing issues or a more persistent challenge in converting growth into cash.

Software Growth Supports Barclays’ Retained Overweight Rating

Despite the delayed federal deployments, several operating indicators remained strong. Software and services revenue increased 43% to $437 million, annual recurring revenue advanced 40% to $1.8 billion, and future contracted bookings reached $15.8 billion.

Axon management described the Dedrone delays as a timing issue rather than evidence of weaker underlying demand. That distinction is important to the longer-term assessment, but the company must still convert contracted opportunities into recognized revenue and cash generation.

What Barclays’ Revised Target Means for Investors

The revised $507 target is materially below the previous $688 estimate and approximately 25% below the broader analyst consensus target cited in the report. TIKR’s separate earnings-based calculation suggests that $507 would represent approximately 37 times its 2028 consensus earnings estimate of $13.82 per share. This is the publication’s calculation, not a disclosed Barclays valuation multiple.

Going forward, the key question is whether Axon can meet its fourth-quarter cash flow expectations, resolve federal deployment delays and sustain software growth. Barclays’ retained Overweight rating indicates continued confidence in the company’s longer-term prospects, but its reduced target underscores the importance of execution. For institutional investors, the distinction between a lower valuation target and an unchanged rating offers a more measured view of the bank’s position: constructive, but increasingly attentive to cash flow and delivery risks.

For a confidential discussion regarding your cross-border banking structure and global wealth management arrangements, contact our senior advisory team.